Ablative immunotherapy
The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Th1 cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
1. A method of inducing an adaptive immune response against a tumor in a patient, the method comprising: generating antigens from the tumor in situ by ablation of the tumor, inducing necrotic death of tumor cells; and administering allogeneic T-cells to the site of the in situ generated antigens thereby creating an immune response that serves as an adjuvant to the uptake of antigens from the ablated tumor whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor immunity.
2. The method of claim 1 further comprising:
administering to the patient a priming composition prior to the generation of antigens in situ, the priming composition comprising allogeneic T-cells to be rejected by the patient's immune system in a manner that induces an allogeneic Th1 immunity; and
permitting the patient's immune system to form anti-allogeneic Th1 immune memory prior to the generation of in situ antigens.
3. The method of claim 1 wherein the ablation is by cryoablation.
4. The method of claim 1 wherein the antigens comprise tumor antigens, heat shock proteins and combinations thereof.
5. The composition of claim 1 wherein the allogeneic cells express high levels of Type 1 cytokines.
6. The composition of claim 1 wherein the allogeneic cells express a high density of CD40L, TRAIL, FasL and combinations thereof on the cell surface.